Damora Therapeutics, Inc. 8-K

What Happened
Damora Therapeutics, Inc. (filed 8-K on May 4, 2026) announced that its Chief Financial Officer, Lori Firmani, will cease serving as CFO effective May 1, 2026. The Board appointed Brian Burkavage, the company’s Senior Vice President, Finance, to serve as principal financial officer and principal accounting officer effective the same date. The company described separation payments and other terms for Ms. Firmani and noted Mr. Burkavage will enter the company’s standard executive indemnification agreement.

Key Details

• Effective date: May 1, 2026 (decision made April 28, 2026; 8-K filed May 4, 2026).
• Separation terms for Lori Firmani: subject to execution/non-revocation of a separation agreement, she will receive benefits under the company’s Executive Separation Benefits Plan; base salary continuation and pro-rated target bonus will be paid in a single lump sum, she will receive a $6,000 health savings account contribution, and all outstanding equity awards will be fully accelerated.
• Brian Burkavage (age 43) appointed principal financial officer; joined Damora in December 2025 as SVP, Finance. Prior roles include SVP Finance & Chief Accounting Officer at IO Biotech (2021–2025), Controller at Passage Bio (2020–2021), Director FP&A at Aclaris (2017–2020), and 11 years at Ernst & Young. He holds a B.A. and M.S.A. from the University of Notre Dame and is a licensed CPA.
• No family relationships or related-party transactions requiring disclosure; Burkavage was not appointed pursuant to any arrangement with other persons.

Why It Matters
A CFO change is a material leadership event for investors because it affects who leads financial reporting, controls, and investor communications. The filing commits to separation payments and acceleration of equity awards, which could affect near-term cash outflows and share-based compensation accounting (though dollar amounts beyond the $6,000 HSA contribution were not specified). The promoted officer has industry and audit experience and a CPA license, which supports continuity in financial oversight and reporting.